Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robot suit helps MS patients walk better?

NCT ID NCT06615947

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a robotic walking system called Atalante could help people with multiple sclerosis walk better. Sixty participants were randomly assigned to either use the robot or receive standard physical therapy for 8 weeks. The main goal was to see if the robot improved walking speed more than conventional rehab.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Atalante self-balancing walking system (robotic exoskeleton)
What this could lead to
If successful, this could offer a new, more effective way to improve walking speed and mobility for people with multiple sclerosis.
What could go wrong
This is a small, completed trial with 60 participants. The results may not apply to all MS patients, and the exoskeleton may not be widely available or affordable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

60 people

The number who actually took part.

Started

Feb 2023

Finished

Mar 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Male or female, between 18 and 75 years of age. * Confirmed diagnosis of MS. * EDSS from 6.0 to 7.0. * Able to maintain the upright position on a daily basis. * Stable course of disease-modifying therapy over the past 6 months. * Clinical comorbidity asymptomatic (i.e., no underlying cardiovascular disease) * Height: between approximately 1.50 m. and 1.90 m. * Willingness to visit the Multiple Sclerosis Center of Catalonia (Cemcat) for testing and training. * Gait disorder conditioned by paresis or hemiparesis associated with ataxia or sensory problems. * Patient having given written consent. Atalante is able to accommodate the following limb lengths: * Thigh: 380-460mm. * Distance between the ground and the joint space of the knee (to be measured while wearing the shoes they intend to wear with Atalante): * 457-607mm for patient with an ankle dorsiflexion ≥ 16° * 457-577mm for patient with an ankle dorsiflexion between 13° et 16° * 457-567mm for patient with an ankle dorsiflexion between 10° et 13° * 457-557mm for patient with an ankle dorsiflexion between 0° and 10° * Hip with less or equal to 460mm when seated. * Maximum weight: 90 kg. Exclusion Criteria: * • Pregnancy. * Starting or switching from fampridine (Fampyra®) in the last 4 weeks. * Height and weight outside the secure standard of safe use, described in the safety guides. * Contraindications for Atalante training (eg, bone instability, history of osteoporosis or osteoporotic fractures). * Subjects under Corticosteroids treatment or relapse. * Changes in disease-modifying and symptomatic therapy for MS during the study period. * Subjects with psychiatric or cognitive comorbidities that may interfere with the trial. * Whose joint centers cannot be aligned Atalante's. * Ranges of motion below: * Knee: 5° extension, 110° flexion * Ankle: 0° dorsiflexion, 9° plantar flexion, 18° inversion and eversion * Hip: 115° flexion, 15° extension, 17° abduction, 10° adduction, 10° * medial rotation, 20° lateral rotation * Severe spasticity (greater than Ashworth 3) or uncontrolled clonus. * Severe concurrent medical diseases: infections, circulatory, heart or lung, pressure sores. * Active implantable medical device.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gait disorders, neurologic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Gait Disorders, Neurologic multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre d'Esclerosi Mútiple de Catalunya (Cemcat) - Barcelona, Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona, 08035, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.